With the approval of the single-dose J&J vaccine, India has five vaccines that have got approval for emergency use. The others are Covishield, Covaxin, Sputnik V and Moderna.
Johnson & Johnson Friday said that it remains committed to bringing the single-dose vaccine and accelerating its availability in India through collaboration with Biological E.
The study, released on bioRxiv, found that J&J’s shot produced roughly five-fold lower levels of antibodies against Delta strain compared to levels raised against an early strain.
J&J said the recipients of its vaccine produced strong neutralising antibodies over the course of at least eight months against all variants, including Delta.
This comes after the US Supreme Court refused to consider J&J’s objections to a 2018 jury finding. The company still faces more than 25,000 lawsuits blaming baby powder for causing cancers.
In late March, workers at a biodefence plant in Baltimore accidentally mixed ingredients of Johnson & Johnson and AstraZeneca vaccines, contaminating 15 million doses.
More than than 8 million Americans have been given J&J’s vaccine, which was haulted after a number of cases of blood clots emerged, especially in young women.
Nobody is safe in a market where competition is stunted and choice limited. For the industry, meaningful reform will have to start with the government itself.
Data shows re-alignment in India’s exports, with Tamil Nadu & Telangana posting strong growth in 2024-25 as traditional heavyweights Gujarat & Maharashtra see declines. Gujarat still leads, though.
Of the total package, $649 million will be utilised for additional hardware, software, and support services, and the remaining for Major Defence Equipment (MDE).
Don’t blame misfortune. This is colossal incompetence and insensitivity. So bad, heads would have rolled even in the old PSU-era Indian Airlines and Air India.
COMMENTS